MedPath
HSA Approval

LOTEMAX STERILE OPHTHALMIC SUSPENSION 0.5%

SIN12601P

LOTEMAX STERILE OPHTHALMIC SUSPENSION 0.5%

LOTEMAX STERILE OPHTHALMIC SUSPENSION 0.5%

October 13, 2004

BAUSCH & LOMB (SINGAPORE) PRIVATE LIMITED

BAUSCH & LOMB (SINGAPORE) PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantBAUSCH & LOMB (SINGAPORE) PRIVATE LIMITED
Licence HolderBAUSCH & LOMB (SINGAPORE) PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

SOLUTION

**DOSAGE AND ADMINISTRATION:** SHAKE VIGOROUSLY BEFORE USING. Steroid Responsive Disease Treatment: Apply one to two drops of Lotemax into the conjunctival sac of the affected eye(s) four times daily. During the initial treatment within the first week, the dosing may be increased, up to 1 drop every hour, if necessary. Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after two days, the patient should be re-evaluated (See PRECAUTIONS – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Post-Operative Inflammation: Apply one to two drops of Lotemax into the conjunctival sac of the operated eye(s) four times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period.

OPHTHALMIC

Medical Information

**INDICATIONS AND USAGE:** Lotemax is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, giant papillary conjunctivitis and seasonal allergic conjunctivitis. Lotemax is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with Lotemax experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with Lotemax and 6% with prednisolone acetate 1%. Lotemax should not be used in patients who require a more potent corticosteroid for this indication. Lotemax is also indicated for the treatment of post-operative inflammation following ocular surgery.

**CONTRAINDICATIONS:** Lotemax, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Lotemax is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

S01BA14

loteprednol

Manufacturer Information

BAUSCH & LOMB (SINGAPORE) PRIVATE LIMITED

BAUSCH & LOMB INC

Active Ingredients

LOTEPREDNOL ETABONATE

5 mg/ml

Loteprednol etabonate

Documents

Package Inserts

Lotemax Sterile Ophthalmic Suspension PI.pdf

Approved: May 17, 2019

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

LOTEMAX STERILE OPHTHALMIC SUSPENSION 0.5% - HSA Approval | MedPath